retatrutide obesity trial First phase 3 data, a Triumph of Science! Eli Lilly's trial of obesity

Available as: Last cited 6 Sept 2023 Urva S, OFarrell L, Du Y, Loh MT, Hemmingway A, Qu H, Alsina-Fernandez J, Haupt A, Milicevic Z, Coskun T (2023) The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying

6

Mitochondrial Dysfunction in Type 2 Diabetes and Obesity Well established data demonstrate that mitochondrial dysfunction, particularly as it relates to the processes of oxidative phosphorylation, is contributory to the development of encephalomyopathy, mitochondrial myopathy, and several age-related disorders that include neurodegenerative diseases, the metabolic syndrome, and diabetes

Clinical studies have shown that semaglutide can cause more weight loss than many older medications like phentermine or orlistat